Thiopurine drugs in the treatment of childhood leukaemia: The influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity

British Journal of Clinical Pharmacology

Volumn 44, Issue 5, 1997, Pages 455-461

  Lennard, L ^a,d   Welch, J C ^b   Lilleyman, J S ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

6 Mercaptopurine metabolism; Pharmacogenetics; Thioguanine nucleotides; Thiopurine methyltransferase

Indexed keywords

CYTARABINE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PURINE NUCLEOTIDE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 0030656430     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00607.x     Document Type: Article

References (27)

1. Gale RP, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 1315-1318.
2. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994; 343: 1188-1190.
3. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther 1991; 50: 663-672.
4. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransterase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992; 2: 148-159.
5. Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-229.
6. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W and Weinshilboum RM. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994; 11: 2135-2138.
7. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-662.
8. Weinshilboum RM, Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 1992; 22: 1055-1071.
9. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common genetic polymorphism. DNA and Cell Biology, 1996; 15: 17-30.
10. Lennard L, Gibson BES, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Childh 1993; 69: 577-579.
11. McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 7: 1897-1902.
12. Chessells JM, Bailey CC, Richards SM. Intensification of treatment improves survival for all children with lymphoblastic leukaemia: results of MRC UKALL X. Lancet 1995; 345: 143-148.
13. Lennard L, Singleton HJ. High performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatog B 1994; 661: 25-33.
14. Lennard L, Singleton H. High performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatog 1992; 583: 83-90.
15. Rostrami-Hodjegan A, Lennard L, Lilleyman JS. The accumulation of mercaptopurine metabolites in age fractionated red blood cells. Br J Clin Pharmacol 1995; 40: 217-222.
16. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of 6-mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance. Br J Cancer 1995, 72: 1004-1006.
17. Welch JC, Lennard L, Morton GCA, Lilleyman JS. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concnetrations after an oral dose. Therap Drug Monit 1997; 19: 382-385.
18. Elion GB. The purine path to chemotherapy. Science 1989; 244: 41-47.
19. Adamson PC, Balis FM, Hawkins ME, Murphy RF, Poplack DG. Desulfuration of 6-mercaptopurine. The basis for the paradoxical cytotoxicity of thiopurines in cultured human cells. Biochem Pharmacol 1993; 46: 1627-1636.
20. Keuzenkamp-Jansen CW, De Abreu RA, Blom HJ, Bokkerink JPM, Trijbels JMF. Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukaemia. Biochem Pharmacol 1996; 51: 1165-1171.
21. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase deficient child with acute lymphoblastic leukaemia. J Pediatr 1991; 119: 985-989.
22. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341: 1151.
23. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993; 68: 186-190.
24. Krynetski EY, Schuetz JD, Galpin AJ, Pui C-H, Relling MV, Evans WE, A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92: 949-953.
25. Tai H-L, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58: 694-702.
26. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; (in press).
27. Krynetski EY, Tai H-L, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279-290.